Tag: FOR

KPN has repurchased 1,533,000 KPN ordinary shares in the period from 14 July to 18 July 2025. The shares were repurchased at an average price of € 4.09 per share for a total consideration of € 6.3m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders.

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

PRESS RELEASE

Disclosure of the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the French Commercial Code and the Article 223-16 of
the Règlement général de l’Autorité des marchés financiers  
(Regulation of the French stock market authority)

Los Angeles, California, July 21, 2025 (GLOBE NEWSWIRE) -- As XRP price breaks through $3.55, returning to the spotlight of top cryptocurrencies, a new wave of investors has turned their attention to a fast-rising but little-known project on the XRP ledger: PBK Miner (PBKMiner XRP Mining).
Given XRP's resilience and strong fundamentals, many XRP holders are now looking to PBK Miner, a next-generation XRP mining program driven by artificial intelligence. By launching a 2-day XRP cloud mining contract, the platform provides investors with a flexible and efficient opportunity to accumulate XRP. The program aims to unlock the market's strong demand for low-threshold, high-liquidity XRP investment products.

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk.